221 related articles for article (PubMed ID: 35738038)
1. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.
Singh B; MahmoudianDehkordi S; Voort JLV; Han X; Port JD; Frye MA; Kaddurah-Daouk R;
Psychiatry Res; 2022 Aug; 314():114655. PubMed ID: 35738038
[TBL] [Abstract][Full Text] [Related]
2. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
3. Ketamine as a novel antidepressant: from synapse to behavior.
Murrough JW
Clin Pharmacol Ther; 2012 Feb; 91(2):303-9. PubMed ID: 22205190
[TBL] [Abstract][Full Text] [Related]
4. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.
Gilbert JR; Zarate CA
Pharmacol Biochem Behav; 2020 Feb; 189():172856. PubMed ID: 31958471
[TBL] [Abstract][Full Text] [Related]
6. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
7. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
[TBL] [Abstract][Full Text] [Related]
9. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Nugent AC; Wills KE; Gilbert JR; Zarate CA
Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
[TBL] [Abstract][Full Text] [Related]
10. Guanosine as a promising target for fast-acting antidepressant responses.
Camargo A; Rodrigues ALS
Pharmacol Biochem Behav; 2022 Jul; 218():173422. PubMed ID: 35732211
[TBL] [Abstract][Full Text] [Related]
11. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
12. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
13. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.
Sydnor VJ; Lyall AE; Cetin-Karayumak S; Cheung JC; Felicione JM; Akeju O; Shenton ME; Deckersbach T; Ionescu DF; Pasternak O; Cusin C; Kubicki M
Transl Psychiatry; 2020 Dec; 10(1):432. PubMed ID: 33319774
[TBL] [Abstract][Full Text] [Related]
14. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
Wilkinson ST; Wright D; Fasula MK; Fenton L; Griepp M; Ostroff RB; Sanacora G
Psychother Psychosom; 2017; 86(3):162-167. PubMed ID: 28490030
[TBL] [Abstract][Full Text] [Related]
15. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.
Krystal JH; Kavalali ET; Monteggia LM
Neuropsychopharmacology; 2024 Jan; 49(1):41-50. PubMed ID: 37488280
[TBL] [Abstract][Full Text] [Related]
16. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
17. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.
Villaseñor A; Ramamoorthy A; Silva dos Santos M; Lorenzo MP; Laje G; Zarate C; Barbas C; Wainer IW
Br J Pharmacol; 2014 Apr; 171(8):2230-42. PubMed ID: 24684390
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review.
Kumar R; Nuñez NA; Joshi N; Joseph B; Verde A; Seshadri A; Cuellar Barboza AB; Prokop LJ; Medeiros GC; Singh B
Bipolar Disord; 2024 Jun; 26(4):321-330. PubMed ID: 38326104
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
